Amgen Inc. $AMGN Shares Sold by Evolve Private Wealth LLC

Key Points

• Evolve Private Wealth LLC cut its Amgen stake by 63.9% in the second quarter, selling 3,508 shares and retaining 1,980 shares valued at approximately $717,000. Institutional investors collectively own 76.5% of Amgen.
• Amgen reported quarterly results above expectations, with EPS of $6.29 and revenue of $10.05 billion, representing 9.5% year-over-year revenue growth. The company issued fiscal 2026 EPS guidance of $22.30–$23.50.
• Amgen’s shares opened at $443.84, near their 12-month high of $445.87, while analysts maintain an average “Hold” rating and a consensus price target of $380.43. The company also declared a quarterly dividend of $2.52 per share, yielding approximately 2.3% annually.

Evolve Private Wealth LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 63.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,980 shares of the medical research company's stock after selling 3,508 shares during the period. Evolve Private Wealth LLC's holdings in Amgen were worth $717,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Adell Harriman & Carpenter Inc. raised its position in shares of Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company's stock worth $7,204,000 after buying an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Amgen in the fourth quarter valued at approximately $22,441,000. Sigma Planning Corp increased its stake in shares of Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company's stock valued at $5,889,000 after acquiring an additional 3,488 shares during the period. National Pension Service increased its stake in shares of Amgen by 4.7% during the fourth quarter. National Pension Service now owns 1,239,549 shares of the medical research company's stock valued at $405,717,000 after acquiring an additional 55,489 shares during the period. Finally, Integrated Advisors Network LLC raised its holdings in Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock worth $6,664,000 after purchasing an additional 6,356 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last ninety days. 0.85% of the stock is owned by company insiders.

Amgen Price Performance

NASDAQ AMGN opened at $443.84 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The stock has a market capitalization of $239.95 billion, a PE ratio of 27.58, a price-to-earnings-growth ratio of 3.17 and a beta of 0.41. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $445.87. The company has a 50 day moving average price of $380.90 and a two-hundred day moving average price of $362.81.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm's revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts predict that Amgen Inc. will post 22.92 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen's dividend payout ratio is currently 62.65%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent analyst reports. Daiwa Securities Group decreased their price target on Amgen from $410.00 to $390.00 and set an "outperform" rating for the company in a research report on Wednesday, May 13th. Truist Financial boosted their price objective on Amgen from $340.00 to $362.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Citigroup upped their price objective on shares of Amgen from $345.00 to $405.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. Guggenheim lifted their target price on shares of Amgen from $343.00 to $388.00 and gave the stock a "neutral" rating in a research report on Monday, August 10th. Finally, Piper Sandler boosted their price target on shares of Amgen from $427.00 to $457.00 and gave the company an "overweight" rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Amgen presently has an average rating of "Hold" and an average target price of $380.43.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source